Utibapril
- Product Name
- Utibapril
- CAS No.
- 109683-61-6
- Chemical Name
- Utibapril
- Synonyms
- Utibapril;FPL-63547;(2S)-5-tert-Butyl-3-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]propanoyl]-2,3-dihydro-1,3,4-thiadiazole-2β-carboxylic acid;1,3,4-Thiadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-2,3-dihydro-, (2S)-
- CBNumber
- CB21116205
- Molecular Formula
- C22H31N3O5S
- Formula Weight
- 449.569
- MOL File
- 109683-61-6.mol
Utibapril Property
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- API0012766
- Product name
- UTIBAPRIL
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $505.31
- Updated
- 2021/12/16
- Product number
- CSN21887
- Product name
- Utibapril
- Packaging
- 5mg
- Price
- $1173
- Updated
- 2021/12/16
Utibapril Chemical Properties,Usage,Production
Uses
Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities.
in vivo
Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. Utibapril (2 μg/kg/day) significantly inhibits vascular ACE activity, and Utibapril (250 μg/kg/day) results in a significant inhibition of plasma ACE. Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited after treatment with the higher doses of utibapril[1]. FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts[2].
References
[1] Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91. DOI:10.1097/00005344-199705000-00018
[2] Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol. 1990 May;100(1):90-4. DOI:10.1111/j.1476-5381.1990.tb12057.x
Utibapril Preparation Products And Raw materials
Raw materials
Preparation Products
Utibapril Suppliers
- Tel
- --
- Fax
- --
- enquiry@leancare.co.uk
- Country
- United Kingdom
- ProdList
- 6446
- Advantage
- 42